Novo Nordisk Enters into Agreement with Bluebird Bio, a Company Currently in Litigation with Errant Gene Therapeutics

Novo Nordisk Enters into Agreement with Bluebird Bio, a Company Currently in Litigation with Errant Gene Therapeutics

Oct 14, 2019 | Bluebird Bio., Business Deal, Errant Gene Therapeutics, Gene Editing, Gene Therapy, Hemophilia, Novo Nordisk

Novo Nordisk and Bluebird Bio., previously known as Genetix and purchased by Third Rock Ventures, will collaborate to develop genome editing treatments for genetic diseases, citing specifically the bleeding disease hemophilia as a target disorder, noted Jonathan...

Pin It on Pinterest